Standout Papers

Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotre... 2021 2026 2022 2024152
  1. Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial (2021)
    Bernard Combe, Alan Kivitz et al. Annals of the Rheumatic Diseases

Immediate Impact

1 from Science/Nature 57 standout
Sub-graph 1 of 21

Citing Papers

Therapeutic advances in rheumatoid arthritis
2024 Standout
JAK inhibition enhances checkpoint blockade immunotherapy in patients with Hodgkin lymphoma
2024 StandoutScience
5 intermediate papers

Works of J. Simón being referenced

Filgotinib versus placebo or adalimumab in patients with rheumatoid arthritis and inadequate response to methotrexate: a phase III randomised clinical trial
2021 Standout
Open-Label Observation of Addition of Etanercept Versus a Conventional Disease-Modifying Antirheumatic Drug in Subjects With Active Rheumatoid Arthritis Despite Methotrexate Therapy in the Latin American Region
2013
and 1 more

Author Peers

Author Last Decade Papers Cites
J. Simón 389 243 82 109 23 638
Bénédicte Mugnier 316 244 92 87 28 686
Kou Katayama 377 124 134 69 29 578
Kenneth M. Nies 326 307 43 72 22 675
Claudia Peña Rossi 308 390 62 71 21 715
Mauro Waldemar Keiserman 518 431 47 224 28 696
Devesh Mewar 325 195 52 113 18 562
R. A. Moura 275 253 72 98 26 561
A. Lamour 252 306 30 65 31 631
Eleonora Ballanti 260 349 59 119 18 632
Shlomit Orgad 131 303 44 148 26 614

All Works

Loading papers...

Rankless by CCL
2026